Skip to main content

Harrow, Inc.

corporate_fare Company Profile

Harrow, Inc.

HROW·NASDAQ·Life Sciences·CIK 0001360214

Harrow is a leading provider of ophthalmic disease management solutions in North America. The company was founded to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For over a decade, Harrow has partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic conditions affecting both the front and back of the eye. These conditions include dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow has expanded its portfolio of U.S. Food and Drug Administration (FDA)-approved ophthalmic products through acquisitions, licensing transactions, and internal investment, primarily focusing on the U.S. and Canadian markets. The company owns U.S. commercial rights to and markets the following products: IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, a low-viscosity gel for ocular surface anesthesia; VEVYE® (cyclosporine ophthalmic solution) 0.1%, a water-free solution for the signs and symptoms of dry eye disease; TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/ml, a steroid injection for certain ophthalmic diseases and vitrectomy visualization; and BYOOVIZ® (ranibizumab-nuna) 0.05mL injection, the first FDA-approved LUCENTIS biosimilar for Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV).

Harrow, Inc. (NASDAQ:HROW) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for HROW at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Harrow Reports Q4 Revenue Beat, Issues Strong 2026 Guidance
  • Harrow Appoints Chief Commercial Officer, Reaffirms Guidance, and Details Strategic Commercial Expansions

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$272.3M
Net Income
-$5.14M
Diluted EPS
-$0.14
Op. Cash Flow
$43.86M
Free Cash Flow
$42.98M
Gross Profit
$204.37M
Operating Income
$30.52M
Cash & Equivalents
$72.93M
Debt / Equity
0.00×
Net Margin
-1.9%
Shares Outstanding
37.23M sh
Source: 10-K · filed 2026-03-02 · accession 0001493152-26-008562
$30.3 -0.36% today
52-week range · as of 2026-11-09 $25.76 – $54.85
Market cap
$1.14B
Volume
911.8K (1.3× avg)
3-mo avg 692.7K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HROW - Filings & News (Page 2)

HROW
Mar 02, 2026, 4:15 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $48.40
Real-time Price: $30.30 info
Change: -$18.10 (-37%) info
Market Cap: $1.141B info
HROW
Feb 02, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.35
Real-time Price: $30.30 info
Change: -$11.05 (-27%) info
Market Cap: $1.141B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets